Business Context and Reporting Period
This Form 8-K Current Report was filed by MaxCyte, Inc. (MXCT) on March 28, 2023, covering events occurring on March 27, 2023. The filing primarily addresses the appointment of a new Chief Financial Officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- Base Salary: $425,000 annually.
- Target Bonus: 45% of base salary.
- Equity Grant: Nonqualified stock option for 350,000 shares at an exercise price of $4.11 per share.
- Vesting Schedule: 25% after 12 months, with the remainder vesting monthly over the subsequent 36 months.
Material Changes
The primary material change is the leadership transition in the finance function:
- Appointment: Douglas J. Swirsky was appointed Chief Financial Officer and principal accounting officer, effective March 27, 2023.
- Departure: Ron Holtz, who served as interim CFO since April 15, 2022, will step down from that role but will continue as Executive Vice President, Administration.
Outlook, Risks, and Contingencies
The filing details a severance agreement contingent on termination without "cause" or resignation for "good reason":
- Standard Termination: Entitles the executive to 9 months of base salary and COBRA coverage.
- Change of Control: If termination occurs within 24 months of a change of control, the executive receives the same 9-month salary and COBRA benefits. Additionally, if termination occurs within 180 days prior to a change of control, all unvested stock options fully accelerate.
- Management Commentary: The filing notes Mr. Swirsky's extensive background in life sciences investment banking and executive leadership at companies including Aavantibio, Rexahn Pharmaceuticals, and GenVec.
Investor Verification Checklist
- Verify the impact of the new CFO's appointment on the company's financial reporting and strategic direction.
- Review the full text of the Severance Agreement (Exhibit 10.1) for specific definitions of "cause," "good reason," and "change of control."
- Assess the dilution impact of the 350,000 share option grant relative to the current outstanding share count.
- Confirm the company's cash position to ensure it can support the new executive compensation package and ongoing operational burn rate.